Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

erlotinib

- PMLiVE

Roche announces positive late-stage results for Gazyva/Gazyvaro in lupus nephritis

The disease affects approximately 1.7 million people worldwide and primarily impacts women

- PMLiVE

AstraZeneca’s Imfinzi recommended by CHMP to treat small cell lung cancer

Approximately 30% of small cell lung cancer patients have limited-stage disease

- PMLiVE

J&J’s subcutaneous Rybrevant receives positive CHMP opinion for advanced lung cancer

The formulation significantly reduces administration time compared to the approved intravenous version

- PMLiVE

NICE approves Vertex’s Casgevy one-time gene therapy for sickle cell disease

About 15,000 people in England are living with the inherited blood disorder

- PMLiVE

Roche shares positive overall survival results for Itovebi in advanced breast cancer

Approximately 56,800 new cases of breast cancer are diagnosed in the UK every year

- PMLiVE

Roche/Sarepta announce two-year results for Duchenne muscular dystrophy gene therapy

The muscle-wasting disorder is estimated to affect one in every 5,000 male births worldwide

- PMLiVE

AstraZeneca receives NICE recommendations for lung cancer drugs Tagrisso and Imfinzi

More than 49,000 people are diagnosed with lung cancer in the UK each year

- PMLiVE

AstraZeneca’s Lynparza recommended by NICE to treat advanced breast cancer

BRCA1 and BRCA2 mutations are responsible for 52% and 32% of hereditary breast cancer cases, respectively

- PMLiVE

Roche gains rights to Innovent Biologics’ ADC candidate in deal worth over $1bn

IBI3009 targets an antigen significantly overexpressed in cancers including small cell lung cancer

- PMLiVE

Amgen’s Imdylltra approved by MHRA to treat small cell lung cancer in adults

SCLC accounts for approximately 15% of all lung cancer diagnoses and progresses rapidly

- PMLiVE

J&J’s Rybrevant/Lazcluze combination approved by EC for EGFR-mutated lung cancer

Alterations in EGFR are among the most common driver mutations in NSCLC patients

- PMLiVE

AstraZeneca’s Tagrisso granted EC approval in EGFR-mutated lung cancer

More than 450,000 people are diagnosed with lung cancer each year in Europe

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links